Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 50

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 50
---
 (collectively, the “Asserted Single Cell Patents”). No case schedule has been set.

7.    Capital Stock

As of September 30, 2025, the number of shares of Class A common stock and Class B common stock issued and outstanding were 116,460,674 and 10,078,872, respectively.The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods:

16

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Class B common stock converted to Class A common stock — — 3,977,961 — 

 8.    Equity Incentive Plans

Stock-based CompensationThe Company recorded stock-based compensation cost for the periods presented as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Cost of revenue$2,011 $2,169 $6,481 $6,127 Research and development11,318 15,978 38,037 50,728 Selling, general and administrative11,935 15,763 39,067 51,354 Total stock-based compensation expense$25,264 $33,910 $83,585 $108,209 Restricted Stock UnitsRestricted stock units (“RSUs”) activity for the nine months ended September 30, 2025 is as follows:Restricted StockUnitsWeighted-AverageGrant Date Fair Value(per share)Outstanding as of December 31, 20246,493,387 $35.55 Granted5,579,963 10.49 Vested(2,267,488)32.54 Cancelled(1,339,829)28.24 Outstanding as of September 30, 20258,466,033 $21.00 Stock OptionsStock option activity for the nine months ended September 30, 2025 is as follows:Stock OptionsWeighted-AverageExercise PriceOutstanding as of December 31, 20244,594,582 $45.37 Exercised(433,463)2.54 Cancelled and forfeited(460,484)66.32